Skip to main content
. 2017 Jun 22;10:3119–3122. doi: 10.2147/OTT.S134523

Table 3.

Efficacy of TKIs in EGFR-mutated squamous carcinoma

Author Total cases TKIs Response rate (%) PFS (months)
Shukuya et al16 16 G 38.0 3.1
Cho et al10 8 G, E 37.5 4.1
Fang et al12 15 G, E 26.7 3.9
Xu et al9 26 G, E, I 30.8 3.98

Abbreviations: E, erlotinib; EGFR, epidermal growth factor receptor; G, gefitinib; I, cotinibwen; PFS, progression-free survival; TKIs, tyrosine kinase inhibitors.